RESUMO
Background: The Women's Androgenetic Alopecia Quality of Life (WAA-QoL) questionnaire is the only available specific instrument to evaluate QoL in female pattern hair loss (FPHL) patients. It is made of 16 questions with 6 alternatives, is self-administered, and has not yet been adapted or validated to Spanish. Objectives: The objective of the study was to translate into Spanish, culturally adapt, and validate the WAA-QoL questionnaire. Methods: The translated version (WAA-QoL-sp) was submitted to 453 general population women by e-mail after authorization by the author, translation, and adaptation to Spanish of the WAA-QoL questionnaire. Results: A total of 453 women were evaluated; the median age was 39 years, and there was high internal consistency: Cronbach's alpha was 0.969 for the WAA-QoL-sp. Study Limitations: Sampling of subjects was from diverse Spanish-speaking countries (such as Mexico, Colombia, Chile, Venezuela, Cuba, and Spain) but not from all Spanish-speaking countries. Conclusions: A Spanish version of the WAA-QoL questionnaire was translated and adapted, which proved to be consistent and a valid tool for assessment of FPHL.
RESUMO
There is no doubt that nobody was prepared for the changes we have been experiencing since the SARS-CoV 2 emerged in China. The occupation of hospitals to deal with this pandemic has raised the implementation of telemedicine to continue monitoring chronic diseases, and dermatology has not been the exception. Likewise, the training of specialists must continue, so digital education is more than ever a useful tool, but also a challenge for our specialty in which direct visualization of the dermatological lesions is often necessary.
Sin duda nadie estaba preparado para los cambios que hemos experimentado a partir de que surgió el SARS-CoV-2 en China. La ocupación de los hospitales para hacer frente a esta pandemia ha planteado la implementación de telemedicina para continuar con la vigilancia de enfermedades crónicas, y la dermatología no ha sido la excepción. Así mismo, la formación de especialistas tiene que continuar, por lo cual la educación digital se ha vuelto una posibilidad, pero también un reto para nuestra especialidad, en la que la visualización directa de las lesiones es muchas veces necesaria.
Assuntos
COVID-19/prevenção & controle , Dermatologia/tendências , SARS-CoV-2 , Dermatopatias , Telemedicina/métodos , COVID-19/epidemiologia , Humanos , México , Pandemias , Consulta Remota , Dermatopatias/diagnóstico , Dermatopatias/terapia , Realidade VirtualRESUMO
Rothmund-Thomson syndrome (RTS) is a rare autosomal recessive disorder presenting with poikiloderma and other clinical features, affecting the bones and eyes and, in type II RTS, presenting an increased risk for malignancy. With about 300 cases reported so far, we present a 13-year follow-up including clinical images, X-rays and genetic analysis. A 13-month-old female started with a facial rash with blisters on her cheeks and limbs at the age of 3 months along with congenital hypoplastic thumbs, frontal bossing and fine hair, eyebrows and eyelashes. The patient was lost to follow-up and returned 12 years later with palmoplantar hyperkeratotic lesions, short stature, disseminated poikiloderma and sparse scalp hair, with absence of eyelashes and eyebrows. Radiographic analysis showed radial ray defect, absence of the thumb and three wrist carpal bones, and reduced bone density. Gene sequencing for the RECQL4 helicase gene revealed a mutation on each allele. RTS is a rare disease, and in this patient we observed the evolution of her skin lesions and other clinical features, which were important for the classification of type II RTS. The next years will provide even more information on this rare disease.
RESUMO
Two recently synthesized oxazolidinones: (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one (DA-7157) and its corresponding pro-drug (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-2-oxo-5-oxazolidinyl) methyl disodium phosphate (DA-7218), have shown very good activity against several Gram positive bacteria, including Nocardia and Mycobacterium. In the present work we evaluated the therapeutic in vivo effects of DA-7218 on Nocardia brasiliensis. We first determined the plasma concentration of the prodrug in BALB/c mice using several doses and then tested its activity in an in vivo experimental actinomycetoma murine model. At the end of treatment, there was a statistically significant difference between the three drug receiving groups (25, 12.5 and 5 mg/kg) and the control group(saline solution) (p=0.001), proving that DA-7218 is effective for the treatment of experimental murine actinomycetoma. This compound could be a potential option for patients affected with mycetoma by Nocardia brasiliensis.
Assuntos
Actinomicose/tratamento farmacológico , Micetoma/tratamento farmacológico , Nocardiose/tratamento farmacológico , Nocardia/fisiologia , Organofosfatos/uso terapêutico , Oxazóis/uso terapêutico , Oxazolidinonas/uso terapêutico , Pró-Fármacos/uso terapêutico , Acetamidas/uso terapêutico , Actinomicose/microbiologia , Animais , Modelos Animais de Doenças , Linezolida , Camundongos , Camundongos Endogâmicos BALB C , Micetoma/microbiologia , Nocardia/efeitos dos fármacos , Nocardiose/microbiologia , Organofosfatos/sangue , Organofosfatos/farmacologia , Oxazóis/sangue , Oxazóis/farmacologia , Oxazolidinonas/farmacologia , Pró-Fármacos/farmacologia , Tetrazóis/sangue , Tetrazóis/farmacologia , Resultado do TratamentoRESUMO
The histologic and immunologic findings on psoriasis have led to the development of biologic therapies for its treatment. Biologic therapies are classified according to their structure as recombinant human proteins, monoclonal antibodies, and fusion proteins. Currently there are five biological drugs approved by the Food and Drug Administration for the treatment of psoriasis; however research studies are being performed to implement a few others. It is important to be familiarized with biological drugs, understand their mechanisms of action, and their adverse effects in order to be able to provide patients the most adequate therapeutical alternative. Advances in biotechnology provide new strategies that act on the immune system. The clinical experience using biological therapies in dermatology is relatively limited and there is a need to define which patients are candidates to receive these drugs. The combination of biologic treatments with traditional drugs needs further research since this could enhance their benefits, limit their toxicity, and reduce costs.